Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course ...

As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings ...

Projected by some analysts as a future blockbuster, Isembyld is the first “muscle-targeted” treatment for the disease and, in ...

Etcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche ...

Once disparaged, reverse mergers have become so popular that some deal experts question whether there are enough quality ...

One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a key ...

Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.

AI is evolving from interactive chats to automated workloads driven by agentic tools, compressing timelines and enabling faster outcomes. A new reference architecture running on the Dell Pro Max with ...

Solstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of ...

The failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s ...

RA Capital has already participated in four biotech financings in September. Meanwhile, Janus Henderson has been the year's most prolific backer of biotech reverse merger deals, according to Gilmartin ...

The California biotech plans to bring its first drug, enabled by licensing technology from a Chinese drugmaker, into clinical ...